Mangiferin inhibits chronic stress-induced tumor growth in colorectal liver metastases via WAVE2 signaling pathway

首页 > 成果 > 详情

认领

导出

Link by DOI

反馈

作者信息关键词期刊信息基础信息归属信息摘要

成果类型：

期刊论文

作者：

Tao, Yiming;Tian, Xuefei;Luo, Jia;Zhu, Hongyi;Chu, Yi;...

作者机构：

[Tao, Yiming] Cent South Univ, Xiangya Hosp, Dept Gen Surg, Changsha 410008, Hunan, Peoples R China.

[Tao, Yiming] Cent South Univ, Xiangya Hosp, Natl Clin Res Ctr Geriatr Disorders, Changsha 410008, Hunan, Peoples R China.

[Tian, Xuefei] Hunan Univ Chinese Med, Coll Integrated Chinese & Western Med, Dept Internal Med, Changsha 410208, Hunan, Peoples R China.

[Luo, Jia] Cent South Univ, Hunan Canc Hosp, Affiliated Tumor Hosp, Dept Surg, Changsha 410013, Hunan, Peoples R China.

[Zhu, Hongyi; Chu, Yi] Cent South Univ, Xiangya Hosp 2, Dept Gastroenterol, Changsha 410011, Peoples R China.

语种：

英文

关键词：

Chronic stress;Colorectal liver metastases;Mangiferin

期刊：

Heliyon

ISSN：

2405-8440

年：

2023

卷：

期：

页码：

e13753

DOI：

10.1016/j.heliyon.2023.e13753

基金类别：

National Natural Science Foundation of China [81372630, U20A20408, 82074450, 81502545]

机构署名：

本校为其他机构

院系归属：

中西医结合学院

摘要：

Background: Evidence indicates that chronic stress promotes progression of colorectal liver me-tastases (CLM). Mangiferin is the active chemical constituent of the rhizomes of Anemarrhena asphodeloides Bunge. Mangiferin (MGF) exerts anti-inflammatory, anti-proliferative, anti-angiogenic, anti-fibrotic and antioxidant effects in a variety of cancers. Its mechanism in chronic stress and tumor growth is still poorly understood. Methods: To investigate the effects of MGF on the CLM and tumor-associated depression, activated hepatic stellate cells (a-HSCs), HT-29 CRC cells, were used in chronic unp...

反馈

产权有误：本人成果被他人认领

数据有误：数据基本信息有误

归属有误：成果的院系归属、机构署名归属有误

其他原因：

验证码：

看不清楚，换一个

确定

取消

成果认领

标题：

用户	作者	通讯作者	--
	请选择	请选择	--

确定

取消

Mangiferin inhibits chronic stress-induced tumor growth in colorectal liver metastases via WAVE2 signaling pathway

反馈

成果认领

提示

该栏目需要登录且有访问权限才可以访问